DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients

Information source: Astellas Pharma Inc
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sleep Initiation and Maintenance Disorders; Primary Insomnia

Intervention: Zolpidem MR (Drug); Estazolam (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Astellas Pharma Inc

Official(s) and/or principal investigator(s):
Use Central Contact, Study Chair, Affiliation: Astellas Pharma Inc

Overall contact:
Clinical Development Administration Department, Email: clinicaltrials_info@jp.astellas.com

Summary

The purpose of the study is to investigate the efficacy and safety of zolpidem modified release (MR) tablet using estazolam (Eurodin) as a comparative drug in patients with primary insomnia.

Clinical Details

Official title: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Zolpidem Modified Release (MR) in Patients With Primary Insomnia

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Total score of Pittsburgh Sleep Quality Index (PSQ)

Secondary outcome:

Physician's clinical global impression (CGI)

Patient's global impression (PG)

Sleep latency, total sleep time, number of awakenings, wake time after sleep onset as derived from sleep diary

Incidence and severity of adverse events, including abnormal sleep behavior

Eligibility

Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of primary insomnia based on DSM-IV criteria (307. 42)

- Written informed consent has been obtained

Exclusion Criteria:

- Patients with sleep apnea syndrome, narcolepsy, presence or suspicion of periodic leg

movement or restless leg syndrome

- Patients with hepatic failure, myasthenia gravis, or hypersensitivity to zolpidem

- Patients who are known to be current drug or alcohol abuser or likely to

concomitantly consume alcoholic beverages (more than 3 times/week)

- Patients who are pregnant, lactating or intend to become pregnant during the study

period

- Patients who have received antidepressants or anxiolytics will not allow to change

the dose or discontinue the previous medication throughout the study

- Any clinically significant condition, which in the opinion of the investigator makes

the patients unsuitable for the trial

- Participation in any clinical trial within 1 month prior to randomization

Locations and Contacts

Clinical Development Administration Department, Email: clinicaltrials_info@jp.astellas.com

Taipei 100, Taiwan; Recruiting
Additional Information

Starting date: May 2009
Last updated: April 8, 2010

Page last updated: October 04, 2010

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014